Non-Interventional Study With Aricept® Evess

Pfizer

Status: Completed

Conditions: Alzheimer's Disease; Vascular Dementia

Treatments: Drug: Aricept® Evess

Study type: Observational

Funder types: Industry

Identifiers

NCT00889603

A2501065

Details and patient eligibility

About

The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.

Enrollment: 370 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Outpatients (male / female), older than 50 years.
• Patients with clinical symptoms of mild and moderate AD and Vascular Dementia.
• MMSE score between 12 - 24.

Exclusion criteria

• Patients with a known hypersensitivity to donepezil clorhydrat, piperidine derivatives or any of the excipients of Aricept® Evess.
• Patients with severe impaired hepatic function.
• Patients with pre-existing gastrointestinal ulcer disease.
• Patients with the history of bronchial asthma or chronic obstructive lung disease.
• Patients with the history of serious atrioventricular conduction disturbances.

Trial design

370 participants in 1 patient group

1

Treatment:

Drug: Aricept® Evess